Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Guodong Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0267-6915; OpenAlex author ID A5055761155. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2017: 3 papers · 2018: 4 papers · 2019: 2 papers · 2020: 6 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 18

  1. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-025-07740-8↗
  2. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  3. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Co-author DOI 10.1155/2021/6530298↗
  4. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  5. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. Co-author DOI 10.1007/s00268-019-05325-z↗
  6. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… First author DOI 10.1016/j.canlet.2020.08.001↗
  7. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-020-2475-3↗
  8. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  9. Optimization of internal reference genes for qPCR in human pancreatic cancer research. First author DOI 10.21037/tcr.2020.02.48↗
  10. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Co-author DOI 10.1016/j.prp.2019.152666↗
  11. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗
  12. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Co-author DOI 10.1002/ijc.31173↗
  13. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Co-author DOI 10.1002/ijc.31657↗
  14. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regul… Co-author DOI 10.1186/s12943-018-0761-9↗
  15. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Co-author DOI 10.2147/ott.s157759↗
  16. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis. Co-author DOI 10.1016/j.canlet.2017.08.032↗
  17. Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis. Co-author DOI 10.18632/oncotarget.15394↗
  18. A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.22861↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 14 shared papers, 2017–2025 · strength 1.40
  2. Yi Miao · 13 shared papers, 2017–2021 · strength 1.11
  3. Qun Chen · 8 shared papers, 2020–2025 · strength 0.99
  4. Wanli Ge · 8 shared papers, 2018–2025 · strength 0.98
  5. Zipeng Lu · 9 shared papers, 2017–2020 · strength 0.69
  6. Hao Yuan · 8 shared papers, 2017–2022 · strength 0.68
  7. Jingjing Zhang · 8 shared papers, 2017–2020 · strength 0.68
  8. Lingdong Meng · 5 shared papers, 2020–2025 · strength 0.67
  9. Peng Shen · 5 shared papers, 2020–2025 · strength 0.67
  10. Xumin Huang · 5 shared papers, 2020–2025 · strength 0.65
  11. Yi Miao · 5 shared papers, 2019–2025 · strength 0.63
  12. Baobao Cai · 6 shared papers, 2018–2021 · strength 0.56
  13. Pengfei Wu · 6 shared papers, 2017–2021 · strength 0.51
  14. Lei Chen · 5 shared papers, 2017–2020 · strength 0.42
  15. Pengfei Wu · 4 shared papers, 2019–2022 · strength 0.40
  16. Tianfang Xia · 5 shared papers, 2018–2020 · strength 0.40
  17. Meng Cao · 4 shared papers, 2019–2021 · strength 0.39
  18. Pengbo Zhang · 4 shared papers, 2019–2021 · strength 0.39
  19. Kuirong Jiang · 4 shared papers, 2017–2020 · strength 0.34
  20. Shouji Cao · 3 shared papers, 2020–2021 · strength 0.31
  21. Yang Feng Wu · 4 shared papers, 2017–2018 · strength 0.27
  22. Xinquan Wu · 3 shared papers, 2019–2020 · strength 0.26
  23. Min Tu · 2 shared papers, 2020–2022 · strength 0.23
  24. Dongfang Liu · 3 shared papers, 2018 · strength 0.21
  25. Yuan Ming He · 2 shared papers, 2018 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.